Editor's Note

This is the first supplement in the Journal since 2007. Supported by Philips Respironics, it focuses on the development and use of the I-neb Adaptive Aerosol Delivery (AAD) System, a so-called “smart nebulizer.” In the medical literature, supplements have often been used as forums for groups who want to make a specific point, and commonly by industry to focus readership on a drug or device. Articles could be ghost written, commercially biased, and published without peer review. Journal of Aerosol Medicine and Pulmonary Drug Delivery has always aspired to the highest standards of editorial excellence, and all supplements that have been published in the Journal have undergone careful editorial scrutiny.

In the last few years, a national awareness of the potential for conflict of interest has grown, casting a pall over industry sponsorship. If we are to move forward and away from this environment, it seems short sighted to think that academic and scientific advancement must always be divorced from industry. The position of the Journal is that full disclosure and peer review are key components of any solution. The readership must be able to make informed choices, knowing who actually did the work, wrote the article, and, in the JAMPDD, the reader will know who reviewed the article. The articles in this supplement, like any publication offering information endorsed by this Editorial Office as original and important for our readership, are accompanied by full disclosure and peer review.